Literature DB >> 29714157

Factors Associated with Wuchereria bancrofti Microfilaremia in an Endemic Area of Mali.

Housseini Dolo1,2, Yaya Ibrahim Coulibaly3,1, Louise Kelly-Hope3, Siaka Konate4, Benoit Dembele5, Siaka Yamoussa Coulibaly1, Dramane Sanogo6, Lamine Soumaoro1, Michel Emmanuel Coulibaly1, Salif Seriba Doumbia1, Abdallah Amadou Diallo1, Sekou Fantamady Traore1, Robert Colebunders2, Thomas B Nutman7, Amy D Klion7.   

Abstract

Although Wuchereria bancrofti (Wb), the causative agent of lymphatic filariasis, is endemic throughout Mali, the prevalence of Wb microfilaremia (Mf) can vary widely between villages despite similar prevalence of infection as assessed by circulating antigen. To examine this variation, cross-sectional data obtained during screening prior to an interventional study in two neighboring villages in Mali were analyzed. The overall prevalence of Wb, as assessed by Wb CAg (circulating antigen), was 50.3% among 373 participants, aged 14-65. Wuchereria bancrofti Mf-positive and negative individuals appeared randomly distributed across the two villages (Moran's I spatial statistic = -0.01, Z score =0.1, P>0.05). Among the 187 subjects positive for Wb CAg, 117 (62.5%) had detectable Mansonella perstans microfilaremia (Mp Mf) and 64 (34.2%) had detectable Wb microfilaremia. The prevalence of Mp microfilaremia was 73.4% in the Wb Mf-positive group (as compared to 56.9% in the Wb Mf-negative group; p=0.01), and median Wb Mf load was increased in co-infected subjects (267Mf/ml vs 100 Mf/ml; p<0.001). In multivariate analysis, village of residence, Mp Mf positivity and gender were significantly associated with Wb Mf positivity. After controlling for age, gender, and village of residence, the odds of being Wb Mf positive was 2.67 times higher in Mp positive individuals (95% confidence interval [1.42-5.01]). Given the geographical overlap between Mp and Wb in Africa, a better understanding of the distribution and prevalence of Mp could assist national lymphatic filariasis control programs in predicting areas of high Wb Mf prevalence that may require closer surveillance.

Entities:  

Mesh:

Year:  2018        PMID: 29714157      PMCID: PMC6086186          DOI: 10.4269/ajtmh.17-0902

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  22 in total

1.  Situational analysis of lymphatic filariasis morbidity in Ahanta West District of Ghana.

Authors:  Michelle C Stanton; Abigail Best; Matthew Cliffe; Louise Kelly-Hope; Nana-Kwadwo Biritwum; Linda Batsa; Alex Debrah
Journal:  Trop Med Int Health       Date:  2015-12-18       Impact factor: 2.622

2.  Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels.

Authors:  Benoit Dembele; Yaya I Coulibaly; Housseini Dolo; Siaka Konate; Siaka Y Coulibaly; Dramane Sanogo; Lamine Soumaoro; Michel E Coulibaly; Salif Seriba Doumbia; Abdallah A Diallo; Sekou F Traore; Adama Diaman Keita; Michael P Fay; Thomas B Nutman; Amy D Klion
Journal:  Clin Infect Dis       Date:  2010-11-01       Impact factor: 9.079

Review 3.  Mansonella perstans filariasis in Africa.

Authors:  Paul E Simonsen; Ambrose W Onapa; Santa Maria Asio
Journal:  Acta Trop       Date:  2010-02-10       Impact factor: 3.112

4.  A community-based study of factors associated with continuing transmission of lymphatic filariasis in Leogane, Haiti.

Authors:  Alexis Boyd; Kimberly Y Won; Shannon K McClintock; Catherine V Donovan; Sandra J Laney; Steven A Williams; Nils Pilotte; Thomas G Streit; Madsen V E Beau de Rochars; Patrick J Lammie
Journal:  PLoS Negl Trop Dis       Date:  2010-03-23

5.  Molecular identification of Wolbachia from the filarial nematode Mansonella perstans.

Authors:  Paul B Keiser; Yaya Coulibaly; Joseph Kubofcik; Abdallah A Diallo; Amy D Klion; Sekou F Traoré; Thomas B Nutman
Journal:  Mol Biochem Parasitol       Date:  2008-05-02       Impact factor: 1.759

6.  Evaluation of Og4C3 antigen ELISA as a tool for detection of bancroftian filariasis under lymphatic filariasis elimination programme.

Authors:  Suman Wattal; A C Dhariwal; P K Ralhan; V C Tripathi; K Regu; S Kamal; Shiv Lal
Journal:  J Commun Dis       Date:  2007-06

7.  Clinical characteristics of post-treatment reactions to ivermectin/albendazole for Wuchereria bancrofti in a region co-endemic for Mansonella perstans.

Authors:  Paul B Keiser; Yaya I Coulibaly; Falaye Keita; Diakaridia Traore; Abdallah Diallo; Dapa A Diallo; Roshanak T Semnani; Ogobara K Doumbo; Sekou F Traore; Amy D Klion; Thomas B Nutman
Journal:  Am J Trop Med Hyg       Date:  2003-09       Impact factor: 2.345

8.  The Impact of Six Annual Rounds of Mass Drug Administration on Wuchereria bancrofti Infections in Humans and in Mosquitoes in Mali.

Authors:  Yaya I Coulibaly; Benoit Dembele; Abdallah Amadou Diallo; Siaka Konaté; Houseini Dolo; Siaka Yamoussa Coulibaly; Salif Seriba Doumbia; Lamine Soumaoro; Michel Emmanuel Coulibaly; Moses J Bockarie; David Molyneux; Thomas B Nutman; Amy D Klion; Yeya T Toure; Sekou F Traore
Journal:  Am J Trop Med Hyg       Date:  2015-06-01       Impact factor: 2.345

9.  Epidemiological and entomological evaluations after six years or more of mass drug administration for lymphatic filariasis elimination in Nigeria.

Authors:  Frank O Richards; Abel Eigege; Emmanuel S Miri; Alphonsus Kal; John Umaru; Davou Pam; Lindsay J Rakers; Yohanna Sambo; Jacob Danboyi; Bako Ibrahim; Solomon E Adelamo; Gladys Ogah; Danjuma Goshit; O Kehinde Oyenekan; Els Mathieu; P Craig Withers; Yisa A Saka; Jonathan Jiya; Donald R Hopkins
Journal:  PLoS Negl Trop Dis       Date:  2011-10-11

10.  A case study of risk factors for lymphatic filariasis in the Republic of Congo.

Authors:  Cédric B Chesnais; François Missamou; Sébastien D Pion; Jean Bopda; Frédéric Louya; Andrew C Majewski; Peter U Fischer; Gary J Weil; Michel Boussinesq
Journal:  Parasit Vectors       Date:  2014-07-01       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.